PT4

PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL) . PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity[1].

Product Specifications

CAS Number

[1280738-47-7]

UNSPSC

12352005

Target

Parasite; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pt4.html

Solubility

10 mM in DMSO

Smiles

O=C1N(CCN2N=NC(C3=CC=CC=C3)=C2)C(C4=C1C=CC=C4)=O

Molecular Formula

C18H14N4O2

Molecular Weight

318.33

References & Citations

Leishmania amazonensisLeishmania braziliensis

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Leishmania

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

FAB10311W 0.5 mL

Mouse Monoclonal ADAM8 Antibody (143338) [DyLight 650]

Ask

View Details

MBS5787091 Inquire

Dihydropyrocurzerenone

Ask

View Details

CR064-0.5ml 0.5 mL

PAX5

Ask

View Details

FAB5385K 0.1 mL

Mouse Monoclonal T-bet/TBX21 Antibody (525803) [DyLight 488]

Ask

View Details

MBS1195111-01 0.02 mg (E-Coli)

Recombinant Xylella fastidiosa Iron-sulfur cluster insertion protein ErpA (erpA)

Ask

View Details

MBS1195111-02 0.1 mg (E-Coli)

Recombinant Xylella fastidiosa Iron-sulfur cluster insertion protein ErpA (erpA)

Ask

View Details